Janux Therapeutics (JANX) Cash & Equivalents (2020 - 2025)
Historic Cash & Equivalents for Janux Therapeutics (JANX) over the last 6 years, with Q3 2025 value amounting to $48.4 million.
- Janux Therapeutics' Cash & Equivalents rose 8086.64% to $48.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.4 million, marking a year-over-year increase of 8086.64%. This contributed to the annual value of $430.6 million for FY2024, which is 214215.05% up from last year.
- As of Q3 2025, Janux Therapeutics' Cash & Equivalents stood at $48.4 million, which was up 8086.64% from $52.4 million recorded in Q2 2025.
- In the past 5 years, Janux Therapeutics' Cash & Equivalents registered a high of $430.6 million during Q4 2024, and its lowest value of $14.7 million during Q2 2024.
- Moreover, its 5-year median value for Cash & Equivalents was $51.9 million (2022), whereas its average is $101.4 million.
- Its Cash & Equivalents has fluctuated over the past 5 years, first plummeted by 8139.94% in 2022, then skyrocketed by 214215.05% in 2024.
- Quarter analysis of 5 years shows Janux Therapeutics' Cash & Equivalents stood at $35.6 million in 2021, then soared by 44.53% to $51.4 million in 2022, then plummeted by 62.66% to $19.2 million in 2023, then skyrocketed by 2142.15% to $430.6 million in 2024, then plummeted by 88.76% to $48.4 million in 2025.
- Its Cash & Equivalents stands at $48.4 million for Q3 2025, versus $52.4 million for Q2 2025 and $73.7 million for Q1 2025.